Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes

Journal of Medical Virology

Volumn 83, Issue 8, 2011, Pages 1377-1382

  Didelot, Marie Noelle ^a,b   Boulle, Nathalie ^a   Damay, Audrey ^a   Costes, Valérie ^a   Segondy, Michel ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

HC2; HPV; PapilloCheck

Indexed keywords

ADULT; ANUS; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIGENE HC2 HPV DNA ASSAY; DNA DETERMINATION; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; SCREENING TEST; SQUAMOUS CELL; SQUAMOUS EPITHELIUM; UTERINE CERVIX BIOPSY; VIRUS TYPING;

ADULT; ANAL CANAL; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; VIROLOGY;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 79959203931     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22148     Document Type: Article

References (32)

1. Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. 2006. Clinical applications of HPV testing: A summary of meta-analysis. Vaccine 24: 78-89.
2. Berry JM, Palefsy JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. 2009. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 52: 239-247.
3. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomaviruses types. Cancer Epidemiol Biomarkers Prev 11: 1394-1399.
4. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 46: 2595-2604.
5. Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, Fishman F, Jay N, Pollack LM, Palefsky JM. 2008. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Anal Intern Med 149: 300-306.
6. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJLM. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26: K29-K41.
7. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. 2009. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 156: 77-83.
8. Damay A, Fabre J, Costes V, Didelot JM, Didelot MN, Boulle N, Segondy M. 2010. Human papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. J Med Virol 82: 592-596.
9. de Roda Husman AM, Walboomers JMM, van den Brule AJC, Meijer CJLM, Snijders PJF. 1995. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacents highly conserved sequences improves human papillomavirus detection by polymerase chain reaction. J Gen Virol l76: 1057-1062.
10. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. 2009. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer 124: 1626-1636.
11. Fox PA, Seet JE, Stebbing J, Francis N, Barton SE, Strauss S, Allen-Mersh TG, Gazzard BG, Bower M. 2005. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: A review of cases from an anoscopy clinic. Sex Transm Infect 81: 142-146.
12. Goldstone SE, Enyinna CS, Davis TM. 2009. Detection of oncogenic human papillomavirus and other predictors of anal high-grade dysplasia in men who have sex with men with abnormal cytology. Dis Colon Rectum 52: 31-39.
13. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38: 357-361.
14. Halfon P, Benmoura D, Khiri H, Penaranda G, Blanc B, Riggio D, Sandri MT. 2010. Comparison of the clinical performance of carcinogenic HPV typing of the linear array and PapilloCheck HPV-screening assay. J Clin Virol 47: 38-42.
15. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ. 2010. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR enzyme immunoassay in population-based cervical screening. J Clin Microbiol 48: 797-801.
16. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. 2009. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124: 2375-2383.
17. Jones J, Powell NG, Tristram A, Fiander AN, Hibbits S. 2009. Comparison of the PapilloCheck DNA micro-array human papillomavirus detection assay with hybrid capture II and PCR-enzyme immunoassay using the GP5+/6+ primer set. J Clin Virol 45: 100-104.
18. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079.
19. Kreimer AR, Clifford GM, Boyle P, Franceschi S. 2005. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475.
20. Matsumoto K, Oki K, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H. 2010. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study. Int J Cancer 128: 2898-2910.
21. Meijer CJ, Snijders PJ, Castle PE. 2006. Clinical utility of HPV genotyping. Gynecol Oncol 103: 12-17.
22. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. 2008. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-520.
23. Muñoz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJL. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
24. Muñoz N, Bosch FX, Castellsagué X, Diaz M, de Sanjosé S, Hammouda D, Shah KV, Meijer CJ. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285.
25. Muñoz N, Castellsagué X, Berrington de Gonzalez A, Gissmann L. 2006. HPV in the etiology of human cancer. Vaccine 24: 1-10.
26. Poljak M, Marin IJ, Seme K, Vince A. 2002. Hybrid capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25: S89-S97.
27. Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kjaer SK, Iftner T. 2010. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 82: 605-615.
28. Smith JH. 2002. Bethesda 2001. Cytopathology 13: 4-10.
29. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer an high-grade cervical lesions: A meta-analysis update. Int J Cancer 121: 621-632.
30. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
31. Wheeler CM, Hunt WC, Schiffman M, Castle PE. 2006. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 194: 1291-1299.
32. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE. 2009. Human papillomavirus genotype distributions: Implications for vaccination and cervical screening in the United States. J Natl Cancer Inst 101: 475-487.